REYON Pharmaceutical Co., Ltd. (KRX:102460)
South Korea flag South Korea · Delayed Price · Currency is KRW
10,920
-90 (-0.82%)
At close: Apr 16, 2025, 3:30 PM KST

REYON Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Operating Revenue
148,300151,071154,039142,801130,034
Upgrade
Other Revenue
-0-0---0
Upgrade
Revenue
148,300151,071154,039142,801130,034
Upgrade
Revenue Growth (YoY)
-1.84%-1.93%7.87%9.82%-1.16%
Upgrade
Cost of Revenue
76,61573,34773,47564,34858,282
Upgrade
Gross Profit
71,68577,72480,56478,45371,752
Upgrade
Selling, General & Admin
64,13864,30666,28663,15161,008
Upgrade
Research & Development
3,3188,3756,7059,7256,584
Upgrade
Other Operating Expenses
1,046981.05942.46958.94884.68
Upgrade
Operating Expenses
72,67075,95176,11676,90970,098
Upgrade
Operating Income
-985.461,7734,4481,5451,654
Upgrade
Interest Expense
-1,253-195.53-122.2-111.19-178.01
Upgrade
Interest & Investment Income
395.9802.87994.76527.96992.16
Upgrade
Earnings From Equity Investments
-4,359-960.18-1,9681,684-475.29
Upgrade
Currency Exchange Gain (Loss)
72.68124.67-91.5512.434.21
Upgrade
Other Non Operating Income (Expenses)
11,2174,938-945.79514.97430.31
Upgrade
EBT Excluding Unusual Items
5,0886,4832,3154,1732,427
Upgrade
Gain (Loss) on Sale of Investments
24.58-3,1834,2621,1251,573
Upgrade
Gain (Loss) on Sale of Assets
323.88732.32317.22547.04367.42
Upgrade
Other Unusual Items
-273.27----
Upgrade
Pretax Income
5,1634,0326,8945,8454,368
Upgrade
Income Tax Expense
1,012448.59-539.77307.51523.26
Upgrade
Earnings From Continuing Operations
4,1513,5837,4345,5373,844
Upgrade
Net Income
4,1513,5837,4345,5373,844
Upgrade
Preferred Dividends & Other Adjustments
--75125-
Upgrade
Net Income to Common
4,1513,5837,3595,4123,844
Upgrade
Net Income Growth
15.85%-51.80%34.25%44.03%-22.27%
Upgrade
Shares Outstanding (Basic)
1818181817
Upgrade
Shares Outstanding (Diluted)
1818181817
Upgrade
Shares Change (YoY)
-0.46%3.03%4.05%1.01%
Upgrade
EPS (Basic)
226.34195.38414.51305.44225.75
Upgrade
EPS (Diluted)
226.00195.00407.18305.00225.75
Upgrade
EPS Growth
15.90%-52.11%33.50%35.10%-23.06%
Upgrade
Free Cash Flow
-17,448-20,225-54,404-105,293-47,708
Upgrade
Free Cash Flow Per Share
-951.29-1102.71-2979.96-5942.30-2801.53
Upgrade
Dividend Per Share
-150.000150.000250.000200.000
Upgrade
Dividend Growth
---40.00%25.00%-41.71%
Upgrade
Gross Margin
48.34%51.45%52.30%54.94%55.18%
Upgrade
Operating Margin
-0.66%1.17%2.89%1.08%1.27%
Upgrade
Profit Margin
2.80%2.37%4.78%3.79%2.96%
Upgrade
Free Cash Flow Margin
-11.77%-13.39%-35.32%-73.73%-36.69%
Upgrade
EBITDA
5,3586,5558,9816,2106,219
Upgrade
EBITDA Margin
3.61%4.34%5.83%4.35%4.78%
Upgrade
D&A For EBITDA
6,3444,7824,5344,6664,565
Upgrade
EBIT
-985.461,7734,4481,5451,654
Upgrade
EBIT Margin
-0.66%1.17%2.89%1.08%1.27%
Upgrade
Effective Tax Rate
19.60%11.13%-5.26%11.98%
Upgrade
Advertising Expenses
81.7476.91106.0956.01152.9
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.